Volume Alert - GILD 101.85 Gilead Sciences $GILD Hit a high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 19, 2014 at 11:38 AM

Volume Alert - GILD 101.85 Gilead Sciences $GILD Hit a high today of 103.32 Closing the day 10:30 at 101.85 -1.86 -1.79% With a day low of 101.01 and a total volume of 3,875,514.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

Update: Gilead's Harvoni Receives Marketing Authorization In Europe
IAEResearch - at Seeking Alpha - 19 mins ago

GILD: 101.83 (-1.88)

Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 27 mins ago
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 28.78 (-0.01), AGN: 213.41 (+0.04), HD: 97.18 (+1.20), ACT: 268.15 (-1.45), GILD: 101.83 (-1.88), PFE: 30.35 (-0.24), COV: 97.88 (-0.21), ALXN: 192.83 (+0.46)

Knight Sells Priority Review Voucher to Gilead
Marketwire Canada - Wed Nov 19, 7:00AM CST
Knight Therapeutics Inc., (TSX:GUD) through one of its wholly owned subsidiaries ("Knight"

, today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV"

. The PRV was granted to Knight in March of this year with the approval of Impavido(R) (miltefosine) for treatment of patients with visceral, mucosal and cutaneous leishmaniasis. Upon closing of the transaction, Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV. Knight was advised in the transaction by global investment banking firm, Jefferies LLC.
GILD: 101.83 (-1.88), GUD.TO: 6.52 (+0.48)

Gilead: Rising Net Income, Zero Debt And Strong R&D Pipeline
Todd Johnson - at Seeking Alpha - Wed Nov 19, 6:45AM CST

GILD: 101.81 (-1.90), BMY: 58.65 (-0.05)

Most active Nasdaq-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 13.83 (+1.07), GILD: 101.81 (-1.90), FB: 73.81 (-0.53), DNDN: 0.13 (-0.02), MSFT: 48.15 (-0.59), INTC: 34.46 (-0.25), GRPN: 7.33 (-0.04), AAPL: 114.21 (-1.26), CSCO: 26.41 (-0.18)

Final Glance: Biotechnology companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 101.81 (-1.90), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)

Stock Market Today: Oil Slump Fuels S&P 500 to Fresh Record High
at The Street - Tue Nov 18, 3:09PM CST
Three cheers for the S&P 500 which closed the session at an all-time high for a fifth-consecutive session.
SPLS: 13.83 (+1.07), ACT: 268.15 (-1.45), HD: 97.18 (+1.20), MDT: 71.88 (-0.59), XOM: 94.78 (-0.09), AGN: 213.41 (+0.04), URBN: 28.78 (-0.01), TJX: 62.24 (+0.60), GILD: 101.81 (-1.90), TOT: 58.24 (-0.16), TGT: 72.15 (+4.64), LOW: 62.14 (+3.61), CVX: 115.75 (+0.28)

Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST

JNJ: 108.36 (-0.47), GILD: 101.81 (-1.90), MRK: 59.42 (-0.47), AMGN: 162.14 (-0.10), ABBV: 65.74 (-0.31), BMY: 58.65 (-0.05), CELG: 106.85 (+0.07)

Stock Movers: Why 4 Big Drug Stocks Are Rising Today
at Investor's Business Daily - Tue Nov 18, 1:38PM CST
Drugmakers clustered near the top of IBD's Stocks On The Move list Tuesday afternoon. Actavis (ACT), an Ireland-based maker of generic and branded drugs, shot up more than 7% in huge volume in Tuesday afternoon trading on the stock market today. That...
AGN: 213.47 (+0.10), VRX: 141.98 (+0.04), ACT: 268.15 (-1.45), TARO: 146.32 (-2.34), GILD: 101.83 (-1.88)

Stock Market Today: S&P 500 Rallies as Oil Falls Below $75 a Barrel
at The Street - Tue Nov 18, 1:23PM CST
The S&P 500 smashes its last intraday record high, moving higher after oil falls below $75 a barrel.
URBN: 28.78 (-0.01), AGN: 213.47 (+0.10), HD: 97.18 (+1.20), ACT: 268.15 (-1.45), TERP: 32.00 (-0.75), MDT: 71.88 (-0.59), GILD: 101.83 (-1.88), SUNE: 21.55 (+0.07), HIMX: 6.59 (+0.15), AAPL: 114.21 (-1.26), NOK: 7.74 (-0.19)

Midday Glance: Biotechnology companies
AP - Tue Nov 18, 12:24PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 101.83 (-1.88), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)

Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni
at The Street - Tue Nov 18, 9:48AM CST
Shares of Gilead Sciences (GILD) were up in morning trading Tuesday after the European Commission granted marketing authorization for its hepatitis C treatment Harvoni.
GILD: 101.83 (-1.88)

Early Glance: Biotechnology companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 101.83 (-1.88), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)

Harvoni cleared in Europe
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 9:15AM CST

GILD: 101.83 (-1.88)

European Commission Grants Marketing Authorization for Gilead's Harvoni(R) (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
Business Wire - Tue Nov 18, 9:07AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir (LDV) with the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved by the European Commission under the tradename Sovaldi(R) in January 2014.
GILD: 101.83 (-1.88)

Next Resistance Level for Gilead Sciences (GILD) is $102.81
Comtex SmarTrend(R) - Tue Nov 18, 8:58AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $100.95 and have already reached the first level of resistance at $101.60. Should the shares continue to rise, the resistance pivots of $102.81 and $104.67 will be of interest.
GILD: 101.83 (-1.88)

Buy Gilead Sciences Now At A Historic Low Valuation
Ken McGaha - at Seeking Alpha - Tue Nov 18, 7:52AM CST

GILD: 101.83 (-1.88)

Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
PR Newswire - Tue Nov 18, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), Apple (NASDAQ:AAPL), Gilead Sciences (NASDAQ:GILD), Kinder Morgan (NYSE:KMI), and Alibaba (NYSE:BABA).
KMI: 40.79 (+0.38), GILD: 101.83 (-1.88), HAL: 47.94 (-0.60), AAPL: 114.21 (-1.26), BABA: 108.09 (-2.72), BHI: 62.85 (-0.70)

Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 101.83 (-1.88), ABBV: 65.75 (-0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FOX News Revamps 2026 Election Coverage Playbook

Revamped Coverage: More Than Just Breaking News Yeah, everyone's clamoring about the midterms, but Fox News is doing more than just flipping on the camera and breaking the news every few minutes this year. They're rolling out the big guns: AI chatbots, flashy graphics, and special shows across multiple platforms. The point? To get viewers practically hooked and give 'em...

NYC's Historic Move to End Horse Carriages by 2028

A New Era for New York City Streets The wheels of progress sometimes turn slowly, but when they do, they can make one hell of a statement. New York City's Council passing Romanch's Law is the kind of bold move one might have thought overdue. But here we are, facing a brave new world where horse-drawn carriages—a symbol of old-time charm to some and unnecessary cruelty...

AULUMU Unveils High-Design ADuo iPhone Case

A Space-Aged Look for Everyday Use In the gadget world, appearances matter but durability matters more. So AULUMU rolls out the ADuo Particle Aramid Fiber Case for iPhone Duo, making a bold claim in the realm of tech accessories. The Backbone: Aramid Fiber Aramid fiber isn't your run-of-the-mill material. We're talking 1500D quality here—strong but feather-light, a...

Baccarat's Luxe Campaign Courts the High-End Traveler

Shining the Spotlight on a Crystal-Clear Vision When Baccarat decides to cast its net over the high-end travel market, they're not doing it with subtlety. Nope, they're going all out, and why wouldn't they? When you've got a brand that's synonymous with luxury, you have to play the part. Enter Adriana Lima, the supermodel who could probably sell sand in the Maldives if...

Infosys Pushes AI Growth with Strong Deal Wins

Riding the AI Wave Who knew Infosys was a lightning rod for AI momentum, eh? With a 29% quarterly surge in AI revenue, the firm's really putting AI strategy at center stage. Considering today's finicky markets, that's not just peanuts. CEO Salil Parekh's swagger is backed by real numbers, seeing AI revenue inch to 10.5% of total haul. This ain't just talk—Infosys is...

Bidease Taps Moloco Veteran Dock Kim for Growth Role

In the rough-and-tumble world of mobile advertising, cutting through the noise with real results is no easy feat. Yet Bidease finds itself riding high on a wave of growth—200% revenue increase over back-to-back years. That's no small potatoes, and now they're topping it off with a savvy hire: Dock Kim, the former revenue honcho at Moloco, is on deck as the new VP of...

Seatrium, Karpowership Push Forward with Powership Deal

Seatrium Dives Deeper with Karpowership Here's a new chapter in the energy game, folks: Seatrium Limited and Karpowership are tightening their ties, sealing a deal to churn out these futuristic Whale Class Powerships. They're not just slapping some paint onto old relics; they're pioneering hydrogen-ready floating power plants that might just light up more than a few...

Ractigen's LiCO™ Platform Hits Extrahepatic Milestones

Breaking New Ground in RNA Therapeutics Hey, in the world of biotech, landing a meaningful delivery system is like striking gold, and it seems Ractigen Therapeutics just found a shiny nugget. Their latest study on the LiCO™ platform, living and breathing in the pages of Molecular Therapy - Nucleic Acids, maps out a path to some serious therapeutic territory. These guys...

WellBe Taps New Tech Chief to Elevate Home Care

In a move that's got the healthcare world buzzing, WellBe Senior Medical just brought in a heavyweight to steer its digital ship. They've appointed Jeffrey Brown as their new Chief Digital & Information Officer. What's shaking? Brown's stepping into the ring to tackle the age-old healthcare dilemma: making tech work smarter, not harder, especially at home. From High-Tech...

Resilience: From Trauma to Shielding Powerhouses

A Childhood Steeped in Shadows If you think it's all Wall Street pulse for me, think again. Sometimes you stumble upon stories that hit the gut with more force than any market crash. Enter David Seymour's tale, wrapped up in his newly released autobiography from Palmetto Publishing, bearing the intriguingly gritty title: From paperboy to Secret Service Special Agent. This...